SPY423.11+2.25 0.53%
DIA339.45+0.67 0.20%
IXIC14,253.27+111.79 0.79%

UPDATE 1-Novavax combined influenza/COVID-19 vaccine shows promise in animal study

05/10/2021 09:40
UPDATE 1-Novavax combined influenza/COVID-19 vaccine shows promise in animal study

Adds details about results, executive comment

- Novavax Inc NVAX.O said on Monday its combined flu and COVID-19 vaccine produced functional antibodies against influenza and the coronavirus in a preclinical study.

The company said the NanoFlu/NVX-CoV2373 vaccine elicited robust responses to both influenza A and B and protected against the SARS-CoV-2 virus. (https://refini.tv/3bg25TM)

"Seasonal influenza and COVID-19 combination vaccines will likely be critical to combating emerging COVID-19 variants," said Russell Wilson, the executive vice president and NanoFlu general manager of Novavax.

Hamsters that received the combined vaccine had heightened levels of COVID-19 antibodies two weeks after the first immunization, which increased significantly after a second dose, compared to animals that received the COVID-19 vaccine, NVX-CoV2373, alone, the company said.

Novavax said it expects to start clinical studies of the combined vaccine by the end of 2021.



(Reporting by Mrinalika Roy and Amruta Khandekar in Bengaluru; Editing by Amy Caren Daniel)

(([email protected]; within U.S. +1 646 223 8780, outside U.S. +91 806749 8325;))